RTP-based AskBio taps former Chimerix exec as chief financial officer
RESEARCH TRIANGLE PARK – Asklepios BioPharmaceutical (AskBio) is tapping a former Chimerix exec to be part of its C-Suite.
The RTP-based clinical stage gene therapy company on Tuesday named Tim Trost as its chief financial officer. He formerly served as CFO at Chimerix, where he took the company through its IPO and four follow-on financings. He was also previously CFO at Argos Therapeutics, a venture-backed immunotherapy company that also went public.
Prior to that, Trost was CFO at InteCardia, a venture-backed cardiac imaging company, and CFO of Coastal Physician Group, a contract provider of emergency room physicians.
“Tim’s financial and strategic leadership experience, as well as his track record of financing clinical-stage biotech companies, will be critical as we enter our next phase of growth that includes expansion of our AAV manufacturing and clinical programs,” said Sheila Mikhail, AskBio CEO, in a statement. “On behalf of our growing team, I welcome Tim and look forward to his contributions.”
AskBio, founded in 2001, is a privately held, clinical-stage gene therapy company dedicated to improving the lives of children and adults with genetic disorders.
The company’s gene therapy platform uses adeno-associated viruses to carry therapeutic genes into human cells. AAVs are small viruses that can infect cells without causing any known diseases.
Original Article Source: WRAL TechWire